# Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing

> **NCT01453920** · PHASE4 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 44 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01453920
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453920, "Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01453920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*